Enzymatica has developed ColdZyme, an oral spray that shortens the duration of colds and alleviates symptoms such as sore throat. The product is sold in Sweden and the UK through contract organisations and via partnership agreements in other markets.
Strong start to the year with increased sales
Enzymatica’s Q1 report shows total net sales of SEK 12.3 million during the first quarter, representing a 30.3 per cent increase compared to SEK 9.4 million in the same period of 2024.
In Sweden, sales rose by SEK 2.3 million, corresponding to a 31.5 per cent growth compared to the same period last year. According to the company, this is a clear sign that that the product is reaching the consumers and that they appreciate it.
Focus on international partnerships
No sales through partners were reported during the quarter. As a result, Enzymatica is now focusing on discussions with potential partners to expand ColdZyme’s international presence.
– Supported by strong patent protection and new clinical evidence, Enzymatica is in an exciting phase – one where we see growth opportunities on the international stage, says CEO Claus Egstrand in the report.
The product is CE-marked under the new European Medical Device Regulation (MDR), enabling launches in new European markets as soon as partnership agreements are signed. Outside Europe, regulatory processes are ongoing and adapted to the requirements of each market.
Publication of study results during the quarter
The first quarter was also an important period for ColdZyme as study results were published in the medical journal The Journal of Physiology at the end of February. The publication is based on both clinical data and in vitro results from research conducted at the University of Kent and the University of Vienna.
Both studies showed that ColdZyme effectively reduces viral load. Participants in the clinical trial also reported fewer sick days and milder symptoms compared to placebo. Professors Glen Davison and Doris Wilflingseder provide more insights into the results here.
CEO outlines strategy for global growth
BioStock spoke with Enzymatica’s CEO, Claus Egstrand, to gain insights into the company’s strong first-quarter performance and what is required to expand ColdZyme into new international markets.
The report shows increased sales in Sweden and the UK, but no partner-driven sales during the quarter. Can you explain the reasons behind this?
– Partners and potential partners have been waiting for the publication of the independent investigator-initiated study results from the University of Kent in a peer-reviewed journal. Publication of study results in a peer-reviewed journal is needed to support advertising claims in such markets as Germany and the United Kingdom. And publication did not take place until February 28th, so discussion of immediate next steps will have only taken place from this date. On top of this is the lead time for manufacturing of the product, which is approximately three months, so any orders from partners in Q1 are not possible.
Which international markets do you see as most promising for ColdZyme going forward, and why?
– The immediate opportunities with the peer-reviewed results are in Europe, where ColdZyme is already certified as a Class III medical device. And the market in Europe offers many market opportunities in terms of market size.
– The natural evolution after Europe is the markets where the registration process can build on MDR certification, for example, Australia, Japan, and the Middle East/ Africa. Market territories, such as the United States and Latin America, have different regulatory approval frameworks that may require longer approval processes. But in terms of absolute opportunity, the United States is always attractive.
– In summary, we have identified a clear regulatory roadmap to ensure that we optimise market opportunities in an orderly fashion.
What are the most important criteria for Enzymatica when evaluating and selecting new business partners?
We have always believed in the Power of 3, i.e., what are the three key success criteria:
- Critical mass and marketing and sales muscle in the cough/cold category
- Deep understanding of the consumer and their needs in the cough/cold category
- A real feeling of building a true partnership to optimise mutual opportunity
What requirements and expectations do potential partners place on Enzymatica as a company and on ColdZyme as a product?
- Quality, Quality, Quality in all we do, as it is their company name and brand
- Strong peer-reviewed clinical study data, including outlook on next studies/claims
- A real feeling of building a true partnership to optimise mutual opportunity
What milestones can we expect from Enzymatica during the remainder of 2025?
– We hope to be able to announce agreements for marketing and sales of ColdZyme with new claims with existing and new partners.
